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Biobanking and Data Sharing: a Plurality of Exchange Regimes 
 




Key activities in biomedicine and related research rely on collections of biological 
samples and related files. Access to such resources in industry and in academic 
contexts has become strategic and represents a central issue in the general framework 
of rising patenting practices and in debates about the knowledge economy. It raises 
important issues concerning the organisation of scientific and medical work, the 
outline of data-sharing guidelines, and science policy’s contribution to the elaboration 
of an adapted framework. This paper presents an ethnographic study of three French 
human biobanks. Building on field work (participant observation and in-depth 
interviews), the study focuses on data access in the concrete practices in biobanks. 
The paper develops a perspective based on an analysis of different exchange regimes. 
We argue that access practices are submitted to the different regimes that can coexist 
and be articulated within the daily activities of each biobank. We also discuss how 
this perspective can further our understanding of biomedical research, and how it 




As industry funding for biomedical research increases and scientists become further 
involved in the capitalisation of knowledge,2 access to scientific data has became a 
central issue. Accessibility is a salient concern in debates about the objectives of 
scientific activities and the boundaries between academic research, the industry and 
the market.3 Positions are polarised between advocates of ‘open science’ and those 
who look for innovation royalties resulting from industrial appropriation.4 This raises 
issues for scientific priority claims, civil litigation and commercial interests, as well as 
national security. 
 
Biobanks are collections of biological samples and associated databases.5 Their 
evaluation and use is a major issue for biomedical research. There is no consensus on 
terminology in regard to these resources, which are designated by diverse terms: 
collections, biological resource centres, biological databases, biorepositories, 
biobanks, to name only a few.6 ‘Biobank’ will be the term used throughout this paper 
for such organised collections. They are an ideal arena for the study of access 
practices, for at least three reasons. First, biobanks emerge in very different contexts 
(academic, industrial, medical, juridical), resulting in a plurality of data access 
policies.7 Second, practices are many and various, despite the implementation of a 
juridical framework.8 Third, in a context of changing relations between universities, 
health public sector and industry, biobanks are ambiguous entities: they might be 
presented as places for archival storage of a cultural patrimony freely accessible for 
relevant activities, or as commercial enterprises with lucrative potential. The terms 
themselves, used to designate such resources illustrate this ambiguity, at least in 
French (cf. ‘biothèque,’ ‘biobanque’). 
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Thus, biobanks are relevant for the analysis of access practices. However, different 
kinds of biobanks raise specific issues. For example, large-scale population-based 
biobanks generate new specific questions about principles engaged in their 
constitution as well as the status of the population.9 In this paper, we focus on 
biobanks involved both in medical and scientific activities but which are not at the 
large-scale population level. We consider data access practices relating only to 
research-oriented use of these biobanks. 
 
Our objective is to study the economy of exchanges that organise the circulation of 
the data (including biological samples) produced in biobanks. What kind of data is 
exchanged? In what forms? Under what conditions? What terms are used by scientists 
to describe their access practices and for justifying their actions? Are they involved in 
the control of data and how? Understanding this economy is critical both at a 
theoretical level and for policy making. 
 
Data access and exchange regimes 
 
Among the numerous works that have questioned access practices, two main areas 
might be identified. On the one hand, various studies address data sharing questions 
from an ethical standpoint. Major issues include informed consent, secondary uses of 
biological samples, and benefit-sharing.10 These studies generally provide normative 
advice, which can be used to regulate practices more adequately.11 On the other hand, 
there are sociological and anthropological studies that address data access questions 
by investigating concrete scientific and day-to-day medical activities.12 But these 
works address less the accessibility than the appropriation of knowledge. The binary 
model “source/requester” often underlies such analyses: first, a scientist produces data 
that are considered as the output of his work; he/she then makes them accessible 
through publication or informal communication; finally, the freely-available data can 
be obtained by other scientists, who can assess, certify and work on them. The data 
serve as an input to their own research. 
 
We argue that this model oversimplifies the real course of scientific activities. A 
scientist is linked simultaneously to several organisations and involved in many 
networks. Consequently, he can conjointly develop different access practices. 
Furthermore, most studies consider data as well established entities. Nevertheless data 
can be described more accurately as highly contingent: they constitute extremely 
heterogeneous entities such as written materials, statistical samples, biological 
material, software, laboratories techniques, etc. Far from standing in a definitive way, 
as neatly packaged and bounded objects, data are combined in a “data stream” in 
which they can be combined and recombined to serve different purposes. Such a view, 
as was proposed by Hilgartner and Brandt-Rauf,13 highlights the fluidity of both 
information and sources that may alter the stream’s content and direction. It requires 
an examination both of the ways in which the entities circulate, and also of their 
status, by studying the ways scientists themselves define them, link them to each 
other, and shape them in several forms. This approach allows an analysis focused on 
the dynamics of an underground economy that permeates scientific and medical 
research. 
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Our aim is to understand how people involved in biobank activity (scientists, doctors, 
administrators, technicians – referred to, generically, from now on as biobankers) 
share and manage their data stream, and how they divide it into autonomous 
segments. In what manner and under which forms do they break up their data stream? 
What are the conventions - formal and informal - that underlie access practices? When 
is it considered opportune to make their data accessible? What portion(s) of the data 
stream they produce do they consider necessary or/and sufficient to make accessible? 
 
In an area as competitive as biomedical research, which is characterised by a division 
of labour between teams from different institutions, scientific collaboration is an 
organisational necessity. In the course of their collaborations, biobankers develop 
ways for evaluating their biological resources: they publish, patent, and develop 
niches by elaborating specific conventions according to the circulation of data. 
Moreover, the domain of genomics has been differently settled, right from the first 
sequencings and the constitution of large biobanks of biological samples.14 Scientists 
have good reason to regulate their data sharing practices, and to follow ethical and 
policy guidelines so as to make their work possible in each case. 
 
Thus, collaboration describes a variety of relations between the parties involved and 
what those parties jointly produce. Also, participants are not involved in the same 
regime. It is precisely this point that we want to address by focusing on exchange 
regimes developed in the daily activities of biobanks. Our study of biobankers 
provides an opportunity for questioning this plurality of possible regimes. Three 
principal exchange regimes have been identified: cooperation, gifting and sub-
contraction. As we shall see, each regime qualifies the link between the stakeholders 
and defines the forms (material, relational, juridical) of the exchange in a particular 
way. 
 
Here, we will emphasise the fundamental characteristics of each of theses regimes. 
Although they are specific and largely incommensurable, we will see that they can 
coexist within a single biobank. But before we develop that analysis, we will set out 
the methods of our inquiry. 
 
Materials and methodologies 
 
We have carried out ethnographic field work in several French biobanks. Three of 
them are reported here. These biobanks were selected in order to include a range of 
sizes, institutional contexts and developmental stages. Here, they are treated 
anonymously using a constructed name that captures their main characteristics: 
 
1. The standardised biobank was created around 1990 by an association of patients. It 
includes collections for more than three hundred genetic diseases (DNA samples from 
all over the world). Its fundamental research activities are oriented towards patients’ 
benefit. As an established biobank involved in many national and international 
networks, its activities are standardised in conformity with several norms. 
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2. The clinical biobank was created in a hospital centre in 1992 in connection with the 
constitution of a longitudinal study organised on a prospective cohort of patients, 
suffering from a chronic joint disease. The collection of DNA samples (from 850 
patients) is related to clinical, biological and radiographic data. The related research 
activities are principally clinically oriented (eg, improving diagnostic and prognostic 
techniques); nevertheless this biobank is also networked with scientists and other 
collections involved in the understanding of fundamental mechanisms in the genesis 
of joint diseases. 
 
3. The certified biobank was created in the 1980s as a tool for biomedical research 
based on sample collections. Nowadays, it is a certified Biological Resource Center15 
that contains around 60,000 samples stored in a specific building on a hospital 
campus. Its activities include dealing with storage of biological samples (DNA, 
tissues, serums), technical and juridical expertise, and scientific studies with both 
public and private partners. 
 
Our methods are inspired by the “constant comparative method of qualitative 
analysis” promoted by Glaser and Strauss.16 We conducted our investigations on 
several biobanks at the same time to emphasize the differences and the similarities. 
By studying the three biobanks simultaneously, we were able to look beyond local 
contingencies in order to shed light on more meaningful patterns. These investigations 
were used to explore the organisational level of biobanks. 
 
Thus several methods were combined. First, we performed situated observations in 
order to follow the actors, to depict their concrete activities and to identify the devices 
they use. Our investigations consisted in following different peoples (scientists, 
doctors, technicians) during a defined period (a day or a whole week) to understand 
their different activities, which are often distributed between several people, and 
involve a variety of tools and locations. The objective was to reconstitute the 
spectrum of the activities and constraints that they have to deal with daily and to 
identify key situations in the functioning of the biobanks. 
 
Next, we conducted thorough interviews with different personnel from each biobank, 
including multiple interviews with certain individuals in order to follow the evolution 
of situations. The interviews were designed to meet a triple objective: 1) to generate 
discourses about the concrete activities of biobanking; 2) to accumulate accounts 
relating to the organisation of the work; 3) to gather discourses dealing with the 
running of each biobank. Our aim was to identify how the biobankers variously justify 
their work. 
 
Finally, during the period that we conducted the situated observations interviews, we 
made a systematic collection of written documents that shed light on the organisation 
of the biobanks’ work. They also helped us to reconstruct each biobank’s life-history 
(institutional, juridical, scientific and medical) and to identify the devices involved in 
the regulation of data exchanges. 
 
These investigations were oriented towards the constitution of a coherent set of 
empirical data that would be sufficiently varied to identify the diversity of situations. 
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However, our analysis here concerns only a portion of these data – that relating to 
access practices. The empirical investigations conducted on these infrastructures have 
permitted us to document several access practices and to specify different exchange 
regimes. 
 
The cooperation regime 
 
Cooperative work can take various forms. The tasks can be accomplished by different 
persons either simultaneously or successively. They can also be realised in egalitarian 
or hierarchical relationships with or without functional specialisation. Some of these 
forms are distinguishable in the biobanking activities. 
 
In the case of the clinical biobank, a cooperative regime has been in place since the 
first steps in its constitution. This collection, which is situated in a hospital service 
dealing with health care activities, includes biological samples related to clinical, 
radiological and biological data. For each sample, three tubes are used to collect 
serum and cells as sources of DNA. When the blood sample is taken, it is subject to 
several treatments (centrifugation, aliquoting, etc.) and is stored in a freezer at -176°F. 
On the other hand, the cells from which DNA is extracted require a sequence of work 
for which cooperation with another team is required, not because of a lack of skills or 
relevant equipments, but for safety reasons. The centrifuging and storing of some 
serum or some caps is certainly possible. But,  
 
‘If we want to extract DNA using phenol-chlorophorm near a 
clinical service, it poses many problems…What is problematic is the 
manipulation of specific, potentially toxic chemical products…There 
is too much danger of contamination and things like that. So we just 
store natural human products, while all laboratory techniques, such 
as DNA extraction, are done in an Inserm’ research laboratory’ 
(the clinical biobank’s manager) 
 
Cooperation with a laboratory specialising in molecular biology allows the extraction 
of DNA without taking risks within the clinical service. By joining with a laboratory 
exclusively involved in research, that component can be accomplished without 
imperilling the hospital service’s persons, patients or medical staff. We note that the 
tubes prepared and labelled in the hospital laboratory are the only element sent to the 
Inserm’s team that performs the DNA extraction. No other information is made 
available at this stage about patient characteristics or any other aspects. This kind of 
cooperation does not cover the totality of the activities of the project, but is limited to 
a single step in the constitution of the collection; it anticipates possible sanitary 
problems. 
 
The relationship between the two teams’ members is grounded on trust. The samples 
freely circulate without a particular contractual mediation. The exchange relies on an 
interpersonal knowledge that is largely sufficient in order to cooperate without 
compromising the quality of the work, nor generating doubt regarding the potential 
uses of the exchanged data. 
 
‘No contract is signed. It’s something freely done by the teams to 
which we send samples. In theory, they are not supposed to use the 
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sent samples. These samples are anonymous, they are not related to 
data files. There is just the sex and the age of the patients. Thus, in 
theory, they don’t have to use them for anything else. That is to say I 
know to whom I send the samples, I know what one will exactly do 
with them’ 
(the clinical biobank’s manager) 
 
Sharing the samples engages the moral responsibility of those involved. They 
accomplish work based on their deep mutual knowledge: the cooperation, rooted in 
the past, largely extends beyond this project of collection. Doctors and scientists go to 
the same places, regularly see each other at meetings or congresses. They circulate in 
interconnected networks and participate in the same group, which makes the project 
less likely to fail as a result of uncooperative behaviour by the partners involved. 
 
This perspective is also shared by other biobankers. For example, similar privileged 
relations underlie exchanges involving all clinicians at the university hospital centre 
(UHC) where the certified biobank is situated. A template agreement specifies the 
rules agreed on for confidentiality, scientific management and technical organisation. 
This template agreement is not redefined for each new collection; it concerns all the 
UHCs’ departmental heads. Only one section differs in all cases: the technical annex 
established with each scientific manager in order to specify what he/she aims to store, 
how it is to be stored, and within which time limits. 
 
‘And here we play an important role because most clinicians don’t 
know what they want to do or what one has to do. Then we work 
together with the clinicians; we have a consulting role that is 
essential for the quality of the samples’ 
(the certified biobank’s manager) 
 
The biobank persons’ skills directly contribute to the elaboration of the technical 
annex. The biobankers make available the clinician’s research project by building up a 
large part of the collection, indeed several biological analyses. 
 
‘Something is allowed to be a part of the ‘storage/research’ if there 
is a consent form and if the scientific manager agrees to authorise 
the access of a part of the tubes, should requests occur. A time limit 
of three or five years could be allowed for his project to succeed. But 
he agrees the principle of data access’ 
(the certified biobank’s manager) 
 
During cooperative work in which the biobank is involved actively in a scientific 
project, the samples are relevant for the category ‘storage/research’. They are not only 
submitted to the cooperation regime, but they are also destined to be made available to 
others for future projects. At that point they become part of another regime, that of the 
gift. 
 
Thus the basis of the cooperation regime is that each participant occupies a territory of 
recognised competences and contributes to perform a project on the basis of 
complementarity and subsidiarity (eg, extracting DNA for the elaboration of a 
collection, realising the storage of the biological samples). In this regime, the 
interpersonal recognition and the moral responsibility are prevalent in the 
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exchanges.17 They are judged sufficient to found relationships between scientists, to 
permit their agreement and to ensure their involvement in cooperative work, although 
other elements are sometimes implemented to shape collective activities (eg, the 
technical annex of the certified biobank). 
 
The gift regime 
 
The second exchange regime elaborates the relations between persons and data on 
another basis. Instead of bringing the persons together in order to reach a shared 
objective that goes beyond the capacity of each, the collaboration is here founded on a 
reciprocity process: each person commits herself in exchange and expects something 
back. 
 
Let us pursue the analysis of the clinical biobank. In parallel with its collaboration 
with an Inserm team to extract DNA, this biobank has established other links for 
technological reasons. Several treatments of the data are performed by the hospital 
service’s doctors. Studies of samples and related data, from all or some of the 850 
patients affected by a chronic joint disease, have been published in medical journals 
or were performed as part of several PhDs. However certain analyses have been 
conducted on a restricted number of patients on which deeper analyses have been 
performed with the help of another team. 
 
‘There are many samples that have been sent, coming from the 180 
patients affected by this disease, to an Evry Genopole laboratory, a 
laboratory with which we have so far studied two genetics 
markers…We decided [to work with them] after talking with the 
scientists at this laboratory. They told us: “we have identified a 
marker that appears interesting in term of susceptibility”. We 
answered: “it should be interesting to test it in terms of severity, so 
we send the samples to you.”’ 
(a hospital doctor involved in biobank activities) 
 
Here again, the data relating to the samples are not communicated; the samples alone 
are sent to the team for studying the agreed genetics markers. But, in contrast to the 
previous scenario where cooperation was an integral part of the elaboration of the 
collection (cf. DNA extraction), here it is not the entire volume of the available 180 
patients’ samples that is sent, only an aliquot. For each sample, only a part was given 
out. Such a policy also protects the biobank as a long term resource. By handing over 
an aliquot of DNA to the team specialising in genetic analysis, the exchange does not 
result in the depletion of the biobank’s collection. On the contrary, the biobankers pay 
attention to their goods in order to conserve them as long as possible, and are able to 
provide more samples for further analyses. On their side, the laboratory’s members 
perform the genetics tests: some employees are principally appointed to the markers 
analysis. This work deserves a fair retribution. 
 
‘In principle, the samples must be used for a precise work…to study 
well defined markers. It is a collaboration with Francis’s team, and 
we try to validate the markers they identified as being involved in the 
susceptibility to the pathology, and particularly to its severity. So we 
enrolled Francis, who was responsible for the project in this 
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laboratory, and the person who was involved in the analysis of the 
genetics tests, we got them involved with the publication’ 
(a hospital doctor involved in biobank activities) 
 
Returning to the work performed on the samples sent by the hospital team, Francis 
and his colleagues take part in authorship. Such an exchange allows the persons to 
agree in their respective commitment to the collaborative work. Authorship of 
scientific papers plays the role of a counter-gift in a relationship of reciprocity. It is a 
sign by which the social relations between scientists are exhibited and challenged18. 
 
Such an issue of reciprocity is also present in the standardised biobank. During its 
first years of existence, most projects of collection were welcome. The biobank was 
constituted by progressively enriching itself with numerous collections. 
 
‘In the beginning, the first five years, we did a lot of free services. 
We didn’t invoice for it, all was free of charge: “come on, send it to 
us and we do it for you, but it is essential for you to work, too”’ 
(the standardised biobank’s manager) 
 
Presently, no scientist can query this biobank in order to obtain help in the collection 
of samples. He/she has first to describe the aim of his/her study and the project has to 
be accepted by the biobank’s scientific committee. The activities of the biobank have 
been codified in the course of its development. The establishment of a convention has 
been necessary. This convention specifies the characteristics of different research 
teams, the objective of the project, the type of samples (human or animal, blood or 
tissue), the number of samples and the desired type of packaging, etc. Moreover, 
scientists date and sign such a convention of collaboration. In this way,  
 
‘They take advantage of all the biobank’s network, of the 
communication service in order to organise a campaign of collect, to 
obtain contacts with the doctors, the hospital centres…And in this 
case, the biobank is a partner’ 
(the standardised biobank’s manager) 
 
Scientists or doctors are thus paired with an experienced partner to constitute their 
own samples: they interact with many collaborators whose technical and juridical 
know-how largely facilitates the management of their collection. On its side, the 
biobank raises its capacities of expertise and increases the volume of samples that are 
stored. As with the clinical biobank, the gift regime regulates a part of the activities of 
the standardised biobanks. On the other hand, the relation of reciprocity is based on a 
written agreement that clarifies the terms of the exchange.19 
 
The gift regime is here strongly rooted. As Mauss explained in 1950, the gift regime 
inextricably links the persons to the things: “the thing given is not inactive. Invested 
with life, often possessing individuality, it seeks... to produce, on behalf of the clan 
and the native soil from which it sprang, an equivalent to replace it”.20 By attributing 
a social significance to the objects that circulate (eg, exchanging data analysis for
authorship), scientists carefully manage their mutual web of obligations. They adhere 
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The subcontracting regime 
 
The two preceding exchange regimes do not cover the full variety of possible 
situations. The relations between participants can be organised differently. That is 
notably the case for certain transactions engaged by the standardised biobank. 
 
‘The external scientists call me, we establish a convention, they send 
me their specimens, I work on them, I invoice for them and I send 
them back… And after that, if he manipulates it, if he doesn’t 
manipulate it, if the specimens are still in the bank, if he has never 
published, we do not mind’ 
(the standardised biobank’s manager) 
 
In such an arrangement, the biobank is not upgraded to the rank of partner, nor to be 
under an obligation to somebody. It participates neither in the formulation nor to the 
conception of a scientific project. On the contrary, scientists or doctors seek the 
biobank’s service for different objectives: either for elaborating a collection, for 
performing sample analysis, or for obtaining juridical expertise on their practices 
regarding biological samples. From this point of view, scientists, doctors and 
industrialists consider the competences held by the biobank as potential resources for 
their own work. Henceforth they are considered as users, and the biobank invoices 
them for the tasks it completes. 
 
‘We have worked with the Curie Institute for a very long time. We 
have provided services for them and we have regularly work 
together since 1991. They are very satisfied, and we are, too. They 
send to us all their specimens and we organise it for them, we 
generate some cell lines for them, we send them back. But it’s not a 
privileged collaboration; they are really one of our best customers’ 
(the standardised biobank’s manager) 
 
The activities of the biobank are considered as provision of services. To provide this 
kind of service, tasks must be carefully calibrated, their durations precisely counted, 
and their costs meticulously calculated. The biobank elaborates a particular mission 
statement where the different planned tasks (sample taking, DNA extraction, samples 
packaging, their securing and their quality) are invoiced to the users, who are 
considered as real customers. 
 
The certified biobank’s actors share this point of view. They have conceived several 
possibilities to regulate their transactions. As we have seen, when the biobank is 
involved in a research project at the UHC, it corresponds to the “storage/research” 
category. On the other hand, when the biobank is a partner strictly involved in the 
storage of the samples that come from the UHC without a related scientific project, it 
refers to the “storage/deposit” category. The samples are not intended to be circulated: 
 
‘he [the doctor] deposits, we do not touch it, that’s his own, it’s in a 
vault and we don’t care more than that’ 
(the certified biobank’s manager) 
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Thus, data access depends, in several ways, on the nature of the biobank’s 
involvement with the UHC. 
 
However, for an ‘external’ customer approaching the biobank - whether an academic, 
or a private laboratory’s member - the exchange is regulated with a contract that 
clarifies different aspects of storage. Then, whoever is responsible for the biobank and 
the potential user must agree regarding the precise terms of the contract. Several 
articles concern storage conditions and sample quality; others concern exclusivity of 
the samples accessed by the depositary; some define the subject for the storage. 
 
‘Because of that, we can’t just deposit anything. For example, one 
can’t deposit the Ebola virus - things that can be used to achieve 
bio-terrorist ends. Biological and viral risk is important in all 
contracts’ 
(the certified biobank’s manager) 
 
The contract aims to frame the modalities of exchange in a different way to the 
framework agreement, which is potentially valid for all the UHC departmental heads. 
Exchange is not based on personal ties. Here, it is submitted to a market regime where 
the customers pay the fees to the biobank for the storage of their samples. That is why 
it the contract is strictly defined, case by case. Nevertheless, it does not exclude the 
trust between the stakeholders. Trust is an essential component for each exchange 
regimes but is expressed differently: constituted as a functional condition of the 
interpersonal relations in the cooperation regime, trust is at the heart of the reciprocity 
in the gift regime, and it constitutes a non-contractual condition of the contract in the 
subcontracting regime. Indeed, the signature of the contract presupposes a prediction 
of the quality of the expertise and on the mobilisation of the persons in their future 
activities for performing the specified mission.22 
 
In this regime, exchange is not based on reciprocity between each stakeholder, who 
expects something back according to their involvement. It is the mission, specifying 
the tasks with a precise deadline, given to a subcontractor that counts first. Thus, 
exchange is neither triggered by performing a shared project, nor founded in a web of 
reciprocal obligations. The market is here fundamental: users exchange the 
technological and the juridical abilities of the biobank for a financial reward. And 
frequently, exchange takes the material form of a written document (eg, convention, 
contract) in which the stakeholders commit themselves to respect the objective in the 
permitted period. 
 
Table I summarises the preceding analysis with a synthesis of the main aspects of 
exchange regimes: 
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Table I. Three exchange regimes 
 
Regimes Cooperation Gift Subcontracting 
organisational 
principle exchange 
shared objective between 
the parties reciprocity mission by project 
status of persons partners obliged contractors 




craft knowledge analysis and authorship 
technical and juridical 
competences of the 
biobank 
relationship egalitarian or hierarchical 
some are obliged to the 
others sellers/customers 
main form 
of agreement moral conventional contractual 
material support 
of agreement 
word and research 
project word and documents 
dated and signed 
juridical form 
place of trust functional condition of relationship 
inherent condition of 
reciprocity 
non-contractual 





A perspective that aims to identify different exchange regimes opens several 
possibilities. First, it allows an understanding of how biobanks are able to concretely 
articulate these regimes, simultaneously or sequentially. A single biobank can be 
mobilised in several collaborations that do not relate to a unique regime of exchange: 
in practice, biobankers regularly cooperate with a team by investing in a relation 
based on the gift/counter gift with one another, while at the same time accomplishing 
a provision of service with a third party constituted as a customer. Some biobanks 
were codified in order to articulate these different exchange regimes. Thus to seize 
data access in its concrete dynamic expressions requires a move away from the 
simplistic, binary “source/requester”model. To insist upon the simultaneity of 
different access practices permits an understanding of their characteristics as 
distributed over several individuals, institutions and locations. 
 
This perspective is the means of escape from a conception that each regime should be 
obligatorily confined to discrete locations (eg, academic research, industry, market). 
Considering of the communication between different places as a continuum, it is 
necessary to improve the terms of the exchange usually assigned to these places: a 
collaboration that is performed within academic research can entirely be submitted to 
the subcontracting regime, just as a collaboration that involves an industrial laboratory 
can be yielded to the gift regime for a part of shared activities. The three exchange 
regimes are suitable for regulating not only university-industry relationships but also 
exchanges within academic research. Depending upon the type of collaboration, one 
task (eg, sample taking, sample conditioning, DNA extraction) can be variously 
conceived as a particular activity from a project shared by several teams (cooperation 
regime), as the counterpart of work involving a reciprocity process (gift regime), or as 
a provision of service submitted for financial reward (subcontracting regime). 
Therefore, the meaning that biobankers attribute to their activities should be taken 
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seriously. Such a standpoint allows us to understand how they articulate several 
conceptions of exchange for permitting the access to only a fragment of the data 
stream they produce. 
 
Finally, this perspective is an opportunity to understand the different ways in which 
biobankers conceive their biological resources and circulate them in various networks. 
Depending upon situations, opportunities and organisational configurations, they 
simultaneously present their resources in different ways - as a private resource, as a 
war chest which preserves threatened richness, as a useful collection relating to a 
large population, etc. Therefore, the uses of collections of biological samples blur 
boundaries between two forms of values: they can serve as a location for an archive 
for cultural patrimony (a library) or as a place for financial business (a bank). These 
two places play similar roles: storing and archiving any precious goods whose value is 
guaranteed by inscriptions and writing activities.23 Nevertheless, to reduce the 
practices of a library to those of a bank is to neglect that, in their concrete practices, 
people attribute different functionalities to them. Thus to focus on exchange regimes 
allows the study of the concrete articulation between several value’s conceptions 
without neglecting their differences, or overwhelming them with a general equivalent 
(eg, ‘open science,’ ‘private science’). 
 
Since the ‘90s, the rising number of collections of biological samples has been a 
salient concern of biomedical research as well as juridical and political concerns. The 
use of database information raise important and complex new questions. Speculations 
about the emergence of ‘information’ as the dominant commodity of the late twentieth 
century focus on the ‘knowledge economy’ and the radical changes that scientific and 
medical activities must make. However, this exclusive vision does not fit with the 
reality of concrete practices: if biobanks introduce some transformations to the 
organisation of scientific work, a large part of the activities still remain the same.24 
We have tried to show this issue here by dwelling on the plurality of exchange 
regimes and of value’s conceptions. One can disregard this plurality in the name of a 
more unified conception. The practice of modern biomedicine related to biobanks is 
however realisable thanks to the concrete articulation of different exchange regimes. 
By neglecting the plurality of concrete practices and, more generally, the contribution 
of all actors involved in the shaping of biomedical regulations (lawyers, politicians, 
but also donors, patients, physicians, and, as emphasised here, scientists), there is the 
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